Next Article in Journal
Long Non-Coding RNA Myoparr Regulates GDF5 Expression in Denervated Mouse Skeletal Muscle
Next Article in Special Issue
Asymmetric Inheritance of Cell Fate Determinants: Focus on RNA
Previous Article in Journal
Catalyzing Transcriptomics Research in Cardiovascular Disease: The CardioRNA COST Action CA17129
Previous Article in Special Issue
Long Non-Coding RNAs in the Regulation of Gene Expression: Physiology and Disease
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
ncRNA
Volume 5
Issue 2
10.3390/ncrna5020032
ncrna-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Sex Differences in Plasma MicroRNA Biomarkers of Early and Complicated Diabetes Mellitus in Israeli Arab and Jewish Patients

by
Ari Meerson
1,2,*,
Azwar Najjar
3,
Elias Saad
3,
Wisam Sbeit
4,
Masad Barhoum
5 and
Nimer Assy
3,6
1
MIGAL Galilee Research Institute, Kiryat Shmona 1101602, Israel
2
Tel Hai Academic College, Upper Galilee 1220800, Israel
3
Department of Internal Medicine A, Galilee Medical Center, Nahariya 89, Israel
4
Department of Gastroenterology, Galilee Medical Center, Nahariya 89, Israel
5
Director, Galilee Medical Center, Nahariya 89, Israel
6
The Azrieli Faculty of Medicine, Bar Ilan University, Safed 5290002, Israel
*
Author to whom correspondence should be addressed.
Non-Coding RNA 2019, 5(2), 32; https://doi.org/10.3390/ncrna5020032
Submission received: 24 January 2019 / Revised: 29 March 2019 / Accepted: 4 April 2019 / Published: 5 April 2019
(This article belongs to the Special Issue Non-Coding RNAs: Variations and Disease)
Browse Figures
Review Reports Versions Notes

Abstract

:
MicroRNAs play functional roles in the etiology of type 2 diabetes mellitus (T2DM) and complications, and extracellular microRNAs have attracted interest as potential biomarkers of these conditions. We aimed to identify a set of plasma microRNAs, which could serve as biomarkers of T2DM and complications in a mixed Israeli Arab/Jewish patient sample. Subjects included 30 healthy volunteers, 29 early-stage T2DM patients, and 29 late-stage T2DM patients with renal and/or vascular complications. RNA was isolated from plasma, and the levels of 12 candidate microRNAs were measured by quantitative reverse transcription and polymerase chain reaction (qRT-PCR). MicroRNA levels were compared between the groups and correlated to clinical measurements, followed by stepwise regression analysis and discriminant analysis. Plasma miR-486-3p and miR-423 were respectively up- and down-regulated in T2DM patients compared to healthy controls. MiR-28-3p and miR-423 were up-regulated in patients with complicated T2DM compared to early T2DM, while miR-486-3p was down-regulated. Combined, four microRNAs (miR-146a-5p, miR-16-2-3p, miR-126-5p, and miR-30d) could distinguish early from complicated T2DM with 77% accuracy and 79% sensitivity. In male patients only, the same microRNAs, with the addition of miR-423, could distinguish early from complicated T2DM with 83.3% accuracy. Furthermore, plasma microRNA levels showed significant correlations with clinical measurements, and these differed between men and women. Additionally, miR-183-5p levels differed significantly between the ethnic groups. Our study identified a panel of specific plasma microRNAs which can serve as biomarkers of T2DM and its complications and emphasizes the importance of sex differences in their clinical application.

1. Introduction

Obesity, the associated type 2 diabetes mellitus (T2DM), and the complications of T2DM are leading health problems in developed countries. Type 2 diabetes mellitus is a metabolic disorder characterized by hyperglycemia, which arises from insufficient pancreatic insulin secretion, insulin resistance in peripheral tissues, and inadequate suppression of glucagon production. Complications of T2DM include vascular damage, blindness, and kidney failure.
MicroRNAs (miRNAs) are short (20–27 nucleotide) endogenous RNA molecules which associate with argonaute proteins to regulate messenger RNA (mRNA) stability and translation [1]. The role of miRNAs in various biological processes, including adipocyte differentiation, metabolic integration, insulin resistance and appetite regulation [2], and the deregulation of many miRNAs in metabolic tissues of obese animals and humans [2,3,4,5], have been characterized. Our own study, among others, showed that miR-221 is up-regulated in the adipose tissue of obese subjects and regulates a cellular metabolism-related protein network, and specifically the adiponectin receptor ADIPOR1, which affects insulin sensitivity [4,6]. MicroRNAs are also functionally involved in the complications of T2DM, such as nephropathy [7,8] and cardiovascular complications [9,10].
MicroRNAs can be remarkably stable in biofluids, and specifically plasma/serum [11,12]. This stability appears to be conferred by the binding of proteins, or encapsulation in lipid vesicles, of the miRNA molecules [13]. The specific profiles of these extracellular miRNAs in biofluids and the particular changes in these profiles under the conditions of disease suggest the potential use of these RNA species as biomarkers useful for diagnosis and stratification of diseases, including metabolic disease [14,15]. The use of human plasma/serum samples for detection of miRNAs can either help to detect early onset of various diseases or provide early clues to the response of patients to drugs. By now, dozens of studies have described subsets of miRNAs which show differential expression in the circulation of T2DM patients; however, meta-analyses show that relatively few miRNA-based biomarkers are informative across multiple studies and/or populations [16,17]. These findings encourage further investigation into the potential clinical use of miRNAs as biomarkers of T2DM and complications.
We aimed to identify a set of blood-borne miRNAs, which could serve as biomarkers of T2DM and complications in a mixed Israeli Arab/Jewish patient cohort.

2. Results

2.1. Plasma microRNAs Show Altered Expression between Subject Groups

To characterize changes in miRNA levels that show association with T2DM and microvascular complications of T2DM, 12 candidate miRNAs (miR-16-2-3p, miR-30d, miR-126-5p, miR-4301, miR-183-5p, miR-27b-3p, miR-146a-5p, miR-28-3p, let-7b-5p, miR-486-3p, miR-122-5p, and miR-423) were measured by quantitative reverse transcription and polymerase chain reaction (qRT-PCR) in RNA isolated from plasma of T2DM patients without diagnosed complications (group B, n = 29), T2DM patients with diagnosed microvascular complications (group C, n = 29), and healthy controls (group A, n = 30). All candidate miRNAs except miR-183-5p could be robustly quantified in >90% of plasma-derived RNA samples, with total missing values for 5, 3, 3, 7, 20, 3, 1, 3, 0, 4, 4, and 2 samples for miR-16-2-3p, miR-30d, miR-126-5p, miR-4301, miR-183-5p, miR-27b-3p, miR-146a-5p, miR-28-3p, let-7b-5p, miR-486-3p, miR-122-5p, and miR-423, respectively. Several candidate miRNAs showed significant differential expression between subject groups (Figure 1A). While the changes in the expression of miR-30d and miR-146a-5p (down-regulation and up-regulation, respectively) was associated with the progression of T2DM, several other miRNAs (miR-183-5p, miR-27b-3p, miR-28-3p, miR-486-3p, miR-423) showed opposite changes of expression in the early T2DM and complicated T2DM groups. For miR-28-3p, miR-486-3p, and miR-423, these differences were statistically significant (Figure 1A).
Multiple stepwise regression analysis was employed to assess the ability of miRNA levels to indicate early vs. complicated diabetes mellitus (DM). This resulted in a combination of four miRNAs (miR-146a-5p, miR-16-2-3p, miR-126-5p, and miR-30d) (Table S2). When incorporating both clinical measurements and plasma miRNA levels, a single miRNA—miR-423—was sufficient to indicate early vs. complicated T2DM with a T value of 3.7, p < 0.001 (Table S2).

2.2. Diabetes Mellitus–Associated Changes in Plasma microRNA Levels Differ between Men and Women

Discriminant analysis showed that the plasma levels of miR-146a-5p, miR-16-2-3p, miR-126-5p, miR-30d, and miR-423 (Table S2) could be used to distinguish between early and complicated T2DM with 76.7% diagnostic accuracy, 79% sensitivity, 75% specificity, 76% positive predictive value, and 22% negative predictive value (Table 1). Repeating the analysis with only the male subjects improved the diagnostic accuracy to 83.3%. Conversely, repeating the analysis with only the female subjects decreased the diagnostic accuracy to 70% (Table 1).
Furthermore, we observed prominent differences between the sex-specific Pearson correlations of specific miRNA levels with clinical measurements (Table 3). Thus, only two of the measured miRNAs showed any significant correlations to any clinical measurements in the entire cohort. However, stratifying the cohort into men and women led to significant observed associations of miRNA levels with multiple anthropometric measurements (Table 3). Specifically, the levels of miR-486-3p showed a strong positive correlation with low-density lipoprotein (LDL) cholesterol levels in women but not in men (Figure 1C), conversely showing a significant negative correlation with high-density lipoprotein (HDL) levels in men but not in women (Figure 1D).

2.3. Ethnicity–Associated Differences in Plasma microRNA Levels and Clinical Parameters

To check if plasma miRNA levels or other clinical parameters differ in association with ethnic affiliation, the subject groups were stratified according to ethnic self-identification as Jew, Muslim Arab, Christian Arab, Druse, or undetermined (Table S11). The Jewish and Muslim Arab groups were chosen for further analysis, as they were the largest two groups in our cohort and included individuals from all 3 clinical categories (A, B, and C).
Of all miRNAs tested, only miR-183-5p levels differed significantly (p = 0.014, t-test) between the ethnic groups as a whole, showing higher average levels in the Muslim Arab subjects in all clinical groups, but especially in group B, where its average levels were >3-fold higher (p = 0.031, t-test) in the Muslim Arabs compared to the Jews (Figure 2A). Additionally, miR-16-2-3p was >2-fold higher (p = 0.02, t-test) in the Muslim Arabs compared to the Jews in group A (healthy controls) but showed no significant differences in groups B or C (Figure 2A).
Comparing other clinical measurements, a significant difference was observed between Muslim Arabs and Jews in group C, with height, systolic, and diastolic blood pressure averages all being higher in the Jews. Only in the case of systolic blood pressure (SBP) was there significant (p = 0.02) difference between Muslim Arabs and Jews from all three clinical categories (A, B, and C) (Figure 2B).

3. Discussion

In this study, we found significant differences between the plasma levels of several miRNAs in subjects with early compared to complicated T2DM, as well as compared to healthy controls, in a mixed Arab/Jewish Israeli population. Several of these miRNAs have been identified previously as potential biomarkers of T2DM or related conditions (miR-30d [18,19], miR-126-5p [18,20], miR-183-5p [21], miR-146a-5p [18,22], miR-28-3p [23,24], miR-122-5p [19,25], and miR-423 [26]), while others have not (miR-16-2-3p, miR-4301, miR-27b-3p, and miR-486-3p). As observed in the case of miR-183-5p and miR-423, the plasma levels of some miRNAs do not always show a linear association with disease progression, but rather a reversal between early and late disease stages. This was shown by our and others’ previous studies, for example [27]. Nor is such a reversal unique to miRNAs; it also occurs with other established pathophysiological hallmarks (for example, kidney output, which may increase in early diabetes and then decline with the accumulation of kidney damage).
The study was limited by its sample size; additionally, there was a mean age difference between the healthy and diabetic subjects, which could potentially introduce an age-related bias between group A and groups B+C. Age-related changes were assessed in prior studies for some of the plasma miRNAs (e.g., miR-146a-5p, which was found to be unchanged) [28,29]. In all statistical tests used in our study, a sex-related difference was apparent.
While most biomarker discovery studies adjust their statistical analyses for sex (along with other confounding variables), most stop short of looking at women and men as two separate subsets where different biomarkers may be relevant to the same overall condition. This, despite the fact that even the applicability of traditional biomarkers of metabolic disease differs significantly between the sexes, as reported previously [30,31]. Given the well-known physiological and endocrine differences between the sexes, it is not surprising that many miRNAs are differentially expressed and differentially regulated in women and men (reviewed, Reference [32]). For example, in our study, miR-486-3p levels showed significant differences between the healthy and early T2DM groups in men but not women. Furthermore, in women, miR-486-3p levels showed a significant positive association with LDL levels, while in men, a significant negative association with HDL levels was observed. Our findings suggest that T2DM biomarker panels based on circulating miRNAs should be formulated separately for men and women for optimal accuracy and sensitivity, and that the eventual standardization of these panels for clinical practice, while desirable, is not straight forward.
An additional source of variability that has to be addressed in T2DM biomarker discovery and validation stems from the different genetic/ethnic background of the subjects, as shown previously [20]. In our study, a mixed Arab/Jewish Israeli population was sampled. Although such a group cannot be considered genetically homogenous, neither is it extremely diverse, as history, archeology, and genetics have all indicated a relatively recent common Middle Eastern origin for both groups (see, for example, Reference [33]). We nevertheless observed significant differences in miRNA levels and blood pressure values between Muslim Arabs and Jews in our sample, which should be tested in larger cohorts. Based on the accumulating data, it is altogether feasible that taking ethnic origin, as well as sex, into account will improve the sensitivity and specificity of miRNA-based biomarkers of DM. More studies with larger sample sizes, as well as a re-evaluation of published data are necessary to broaden our understanding of genetic and sex-based effects on circulating miRNA profiles.
Increasing evidence supports endocrine function of circulating miRNAs [34,35]. For example, miR-122-5p, the dominant miRNA in the liver and a known tumor suppressor [36,37], has been shown to be transferred between cells [38] and our and others’ studies have showed that its levels in circulation are altered following bariatric surgery [25,39]. Furthermore, any doubt of the physiological relevance of such signaling by extracellular miRNAs has been put to rest by recent studies [40]. It is therefore imperative to explore the roles of miRNAs and other ncRNAs both as biomarkers and effector molecules in metabolic diseases, roles that can potentially be exploited for prognostic and/or therapeutic purposes.

4. Materials and Methods

4.1. Ethics and Study Participants

The study was approved by the Research Ethics Committee of the Galilee Medical Center, Nahariya, Israel (0090-15-NHR), and participants gave fully informed oral and written consent. Eighty-eight subjects were recruited during the years 2015–2016 at the Department of Internal Medicine A, the Galilee Medical Center, Nahariya, Israel. The sample size was calculated according to Lee et al. [41] using a calculator available online (http://sph.umd.edu/department/epib/sample-size-and-power-calculations-microarray-studies) and the following assumptions: E(R0) = 0.5, G0 = 6, power = 0.9, |μ1| = 0.6, σ0 = 1. The subjects consisted of the following groups:
  • Healthy volunteers (to serve as baseline) with normal response to glucose and insulin and no known renal or vascular pathologies;
  • Early-stage T2DM with no known renal or vascular pathologies;
  • Late-stage T2DM with renal and/or vascular complications including retinopathy or peripheral artery disease (PAD).
Inclusion criteria (T2DM) included ages 20–80, T2DM with proteinuria, T2DM with retinopathy, T2DM with peripheral vascular disease. Inclusion criteria (healthy) included ages 20–80, no diagnosis of metabolic syndrome, no overweight, no diagnosis of T2DM, no concomitant medications. Exclusion criteria included cancer, dialysis, pregnancy, inability to sign informed consent, and patient choice. T2DM was defined as one of the following: Fasting plasma glucose level ≥7.0 mM (126 mg/dL); plasma glucose ≥11.1 mM (200 mg/dL) two hours after a 75 g oral glucose load (glucose tolerance test); symptoms of high blood sugar and casual plasma glucose ≥11.1 mM (200 mg/dL); or glycated hemoglobin (HbA1C) ≥6.5% as per Diabetes Control and Complications Trial (DCCT) guidelines. Peripheral artery disease was defined as: Nontraumatic limb amputation; limb bypass surgery or percutaneous revascularization; a history of intermittent claudication with ankle-brachial pressure index (ABPI) <0.80 in at least one side; or previous carotid endarterectomy. Retinopathy was defined by ophthalmologic examination such as: Leaking blood vessels; retinal swelling, such as macular edema; pale fatty deposits on the retina (exudates); damaged nerve tissue (neuropathy); and similar changes in the blood vessels. Height, weight, medical historical data, and resting vital signs were recorded at the time of enrollment. Approximately 70% of the subjects were Israeli Arabs (predominantly Muslim), and 25% were Israeli Jews, most of them Sephardi. The distribution of anthropometric measurements and ethnographic data in the participant groups are provided in Table S1. Ten milliliters of venous blood were collected in standard anticoagulant Ethylenediaminetetraacetic acid (EDTA)-treated vacutainer tubes. All blood samples were centrifuged at 2000 g for 10 min to pellet cellular elements immediately after blood draw. To minimize freeze–thaw degradation, the supernatant plasma was aliquoted and immediately frozen at –80 °C. To remove any remaining cellular contents, thawed plasma samples were centrifuged at 15,700 g for 10 min, and plasma supernatant was aliquoted into 200 μL volumes for storage at −80 °C for further analysis.

4.2. RNA Isolation and Quantification of Microrna Levels

Previously, we systematically compared several methods of RNA extraction from plasma [42]. Total RNA isolation used the QIAGEN miRNeasy Serum/Plasma kit (Cat. 217184, QIAGEN, Valencia, CA, USA), with an elution volume of 14 µL nuclease-free water. Samples were lysed in QIAzol lysis reagent (QIAGEN, Cat. 79306). After elution, samples were stored at −80 °C. Reverse transcription and qPCR for candidate miRNAs were performed using TaqMan Advanced miRNA assays (Thermo Fisher Scientific, Waltham, MA USA), with a scaled-down version of the manufacturer’s protocol. Briefly, the polyadenylation of miRNAs was performed in a final volume of 3 µL using 2 µL of RNA; adapter ligation was performed in a final volume of 9 µL; reverse transcription was performed in a final volume of 18 µL; the miR-Amp reaction was performed in a final volume of 30 µL; and qPCR was performed in a final volume of 5 µL, in duplicates, on an Applied Biosystems ABI-7900HT Sequence Detection System equipped with a 384-well block (Thermo Fisher Scientific).

4.3. Choice of Tested microRNAs

Candidate miRNAs were gathered from 11 published studies of miRNAs showing altered levels in the plasma/serum of subjects with diabetes [18,19,20,21,22,23,24,25,26,43,44]. Additionally, we used our own unpublished profiling results. We focused on 12 candidate miRNAs: miR-16-2-3p, miR-30d [18,19], miR-126-5p [18,20], miR-4301, miR-183-5p [21], miR-27b-3p, miR-146a-5p [18,22], miR-28-3p [23,24], let-7b-5p [43,44], miR-486-3p, miR-122-5p [19,25,27], and miR-423 [26].

4.4. Statistical Analysis

Results were analyzed with sequence detection system (SDS) 2.3 (Applied Biosystems), Microsoft Excel, WinSTAT, and StatPlus Mac LE (AnalystSoft, Walnut, CA, USA) software. To account for differences in RNA amounts between the individual samples, global normalization of qRT-PCR data was performed, using the median value of relative concentrations for all miRNAs per sample. In our prior studies, e.g., [45], this method has proven to be more robust than relying on specific normalizers. Samples with missing values for a particular miRNA were excluded from downstream analyses involving that miRNA. Student’s t-test was used to evaluate differences between groups. Associations between miRNA and clinical variables were assessed using Pearson Correlations, univariate regression and multivariate stepwise regression analyses. Differences were considered statistically significant at p < 0.05. Subjects with missing data were excluded from the relevant tests.

Supplementary Materials

The following are available online at https://www.mdpi.com/2311-553X/5/2/32/s1, Table S1: Clinical measurements and ethnic/religious affiliations of the participant groups, Table S2: Multiple stepwise regression analysis to distinguish early vs. complicated DM using a panel of plasma miRNAs.

Author Contributions

Conceptualization, A.M. and N.A.; methodology, A.M. and N.A.; formal analysis, A.M., A.N., and N.A.; investigation, A.M., A.N., and N.A.; resources, E.S., W.S., M.B., and N.A.; data curation, E.S., W.S., M.B., and N.A.; writing—original draft preparation, A.M.; writing—review and editing, A.M. and N.A.; supervision, M.B. and N.A.; project administration, A.M. and N.A.; funding acquisition, A.M.

Funding

This research was funded by a Diabetes Research Grant from D-Cure and the Ministry of Health, Israel, to AM, and by the European Union’s FP7-REGPOT-2012-2013-1, Agreement No 316157 (“CEREHA”).

Acknowledgments

We thank Hila Yehuda, MIGAL and Nelly Bar-Guy, Galilee Medical Center for skilled technical and administrative assistance.

Conflicts of Interest

The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.

References

  1. Bartel, D.P. MicroRNAs: Target recognition and regulatory functions. Cell 2009, 136, 215–233. [Google Scholar] [CrossRef] [PubMed]
  2. Heneghan, H.M.; Miller, N.; Kerin, M.J. Role of microRNAs in obesity and the metabolic syndrome. Obes. Rev. 2010, 11, 354–361. [Google Scholar] [CrossRef] [PubMed]
  3. Chartoumpekis, D.V.; Zaravinos, A.; Ziros, P.G.; Iskrenova, R.P.; Psyrogiannis, A.I.; Kyriazopoulou, V.E.; Habeos, I.G. Differential Expression of MicroRNAs in Adipose Tissue after Long-Term High-Fat Diet-Induced Obesity in Mice. PLoS ONE 2012, 7, e34872. [Google Scholar] [CrossRef] [PubMed]
  4. Meerson, A.; Traurig, M.; Ossowski, V.; Fleming, J.M.; Mullins, M.; Baier, L.J. Human adipose microRNA-221 is upregulated in obesity and affects fat metabolism downstream of leptin and TNFα. Diabetologia 2013, 56, 1971–1979. [Google Scholar] [CrossRef]
  5. Mentzel, C.M.J.; Anthon, C.; Jacobsen, M.J.; Karlskov-Mortensen, P.; Bruun, C.S.; Jørgensen, C.B.; Gorodkin, J.; Cirera, S.; Fredholm, M. Gender and Obesity Specific MicroRNA Expression in Adipose Tissue from Lean and Obese Pigs. PLoS ONE 2015, 10, e0131650. [Google Scholar] [CrossRef] [PubMed]
  6. Lustig, Y.; Barhod, E.; Ashwal-Fluss, R.; Gordin, R.; Shomron, N.; Baruch-Umansky, K.; Hemi, R.; Karasik, A.; Kanety, H. RNA-Binding Protein PTB and MicroRNA-221 Coregulate AdipoR1 Translation and Adiponectin Signaling. Diabetes 2014, 63, 433–445. [Google Scholar] [CrossRef]
  7. Hagiwara, S.; McClelland, A.; Kantharidis, P. MicroRNA in Diabetic Nephropathy: Renin Angiotensin, AGE/RAGE, and Oxidative Stress Pathway. J. Diabetes Res. 2013, 2013. [Google Scholar] [CrossRef]
  8. Li, R.; Chung, A.C.K.; Yu, X.; Lan, H.Y. MicroRNAs in Diabetic Kidney Disease. Int. J. Endocrinol. 2014, 2014, 593956. [Google Scholar] [CrossRef] [PubMed]
  9. Figueira, M.F.; Monnerat-Cahli, G.; Medei, E.; Carvalho, A.B.; Morales, M.M.; Lamas, M.E.; da Fonseca, R.N.; Souza-Menezes, J. MicroRNAs: Potential therapeutic targets in diabetic complications of the cardiovascular and renal systems. Acta Physiol. 2014, 211, 491–500. [Google Scholar] [CrossRef]
  10. Rawal, S.; Manning, P.; Katare, R. Cardiovascular microRNAs: As modulators and diagnostic biomarkers of diabetic heart disease. Cardiovasc. Diabetol. 2014, 13, 44. [Google Scholar] [CrossRef] [PubMed]
  11. Weber, J.A.; Baxter, D.H.; Zhang, S.; Huang, D.Y.; Huang, K.H.; Lee, M.J.; Galas, D.J.; Wang, K. The MicroRNA Spectrum in 12 Body Fluids. Clin. Chem. 2010, 56, 1733–1741. [Google Scholar] [CrossRef] [PubMed]
  12. Zampetaki, A.; Willeit, P.; Drozdov, I.; Kiechl, S.; Mayr, M. Profiling of circulating microRNAs: From single biomarkers to re-wired networks. Cardiovasc. Res. 2012, 93, 555–562. [Google Scholar] [CrossRef] [PubMed]
  13. Cheng, L.; Sharples, R.A.; Scicluna, B.J.; Hill, A.F. Exosomes provide a protective and enriched source of miRNA for biomarker profiling compared to intracellular and cell-free blood. J. Extracell. Vesicles 2014, 3. [Google Scholar] [CrossRef] [PubMed]
  14. Guay, C.; Regazzi, R. Circulating microRNAs as novel biomarkers for diabetes mellitus. Nat. Rev. Endocrinol. 2013, 9, 513–521. [Google Scholar] [CrossRef] [PubMed]
  15. Ghai, V.; Wang, K. Recent progress toward the use of circulating microRNAs as clinical biomarkers. Arch. Toxicol. 2016, 90, 2959–2978. [Google Scholar] [CrossRef] [PubMed]
  16. Zhu, H.; Leung, S.W. Identification of microRNA biomarkers in type 2 diabetes: a meta-analysis of controlled profiling studies. Diabetologia 2015, 58, 900–911. [Google Scholar] [CrossRef]
  17. He, Y.; Ding, Y.; Liang, B.; Lin, J.; Kim, T.-K.; Yu, H.; Hang, H.; Wang, K. A Systematic Study of Dysregulated MicroRNA in Type 2 Diabetes Mellitus. Int. J. Mol. Sci. 2017, 18, 456. [Google Scholar] [CrossRef]
  18. Seyhan, A.A.; Nunez Lopez, Y.O.; Xie, H.; Yi, F.; Mathews, C.; Pasarica, M.; Pratley, R.E. Pancreas-enriched miRNAs are altered in the circulation of subjects with diabetes: A pilot cross-sectional study. Sci. Rep. 2016, 6, 31479. [Google Scholar] [CrossRef]
  19. De Candia, P.; Spinetti, G.; Specchia, C.; Sangalli, E.; La Sala, L.; Uccellatore, A.; Lupini, S.; Genovese, S.; Matarese, G.; Ceriello, A. A unique plasma microRNA profile defines type 2 diabetes progression. PLoS ONE 2017, 12, e0188980. [Google Scholar] [CrossRef]
  20. Wang, X.; Sundquist, J.; Zöller, B.; Memon, A.A.; Palmér, K.; Sundquist, K.; Bennet, L. Determination of 14 Circulating microRNAs in Swedes and Iraqis with and without Diabetes Mellitus Type 2. PLoS ONE 2014, 9, e86792. [Google Scholar] [CrossRef]
  21. Flowers, E.; Kanaya, A.M.; Fukuoka, Y.; Allen, I.E.; Cooper, B.; Aouizerat, B.E. Preliminary evidence supports circulating microRNAs as prognostic biomarkers for type 2 diabetes. Obes. Sci. Pract. 2017, 3, 446–452. [Google Scholar] [CrossRef] [PubMed]
  22. Kong, L.; Zhu, J.; Han, W.; Jiang, X.; Xu, M.; Zhao, Y.; Dong, Q.; Pang, Z.; Guan, Q.; Gao, L.; et al. Significance of serum microRNAs in pre-diabetes and newly diagnosed type 2 diabetes: A clinical study. Acta Diabetol. 2011, 48, 61–69. [Google Scholar] [CrossRef] [PubMed]
  23. Zampetaki, A.; Kiechl, S.; Drozdov, I.; Willeit, P.; Mayr, U.; Prokopi, M.; Mayr, A.; Weger, S.; Oberhollenzer, F.; Bonora, E.; et al. Plasma MicroRNA Profiling Reveals Loss of Endothelial MiR-126 and Other MicroRNAs in Type 2 Diabetes. Circ. Res. 2010, 107, 810–817. [Google Scholar] [CrossRef]
  24. Jimenez-Lucena, R.; Rangel-Zúñiga, O.A.; Alcalá-Díaz, J.F.; Lopez-Moreno, J.; Roncero-Ramos, I.; Molina-Abril, H.; Yubero-Serrano, E.; Caballero-Villarraso, J.; Delgado-Lista, J.; Castaño, J.P.; et al. Circulating miRNAs as predictive biomarkers of type 2 diabetes mellitus development in coronary heart disease patients from the CORDIOPREV study. Molec. Ther. Nucleic Acids 2018, 12, 146–157. [Google Scholar] [CrossRef] [PubMed]
  25. Blum, A.; Yehuda, H.; Geron, N.; Meerson, A. Elevated Levels of miR-122 in Serum May Contribute to Improved Endothelial Function and Lower Oncologic Risk Following Bariatric Surgery. Isr. Med. Assoc. J. 2017, 19, 620–624. [Google Scholar] [PubMed]
  26. Ortega, F.J.; Mercader, J.M.; Moreno-Navarrete, J.M.; Rovira, O.; Guerra, E.; Esteve, E.; Xifra, G.; Martínez, C.; Ricart, W.; Rieusset, J.; et al. Profiling of circulating microRNAs reveals common microRNAs linked to type 2 diabetes that change with insulin sensitization. Diabetes Care 2014, 37, 1375–1383. [Google Scholar] [CrossRef]
  27. Pastukh, N.; Meerson, A.; Kalish, D.; Jabaly, H.; Blum, A. Serum miR-122 levels correlate with diabetic retinopathy. Clin. Exp. Med. 2019. [Google Scholar] [CrossRef]
  28. Hooten, N.N.; Fitzpatrick, M.; Wood, W.H.; De, S.; Ejiogu, N.; Zhang, Y.; Mattison, J.A.; Becker, K.G.; Zonderman, A.B.; Evans, M.K. Age-related changes in microRNA levels in serum. Aging 2013, 5, 725–740. [Google Scholar] [CrossRef]
  29. Sawada, S.; Akimoto, T.; Takahashi, M.; Sakurai, R.; Shinkai, S.; Ushida, T.; Fujiwara, Y.; Suzuki, K. Effect of Aging and Sex on Circulating MicroRNAs in Humans. Adv. Aging Res. 2014, 2014. [Google Scholar] [CrossRef]
  30. Newbern, D.; Gumus Balikcioglu, P.; Balikcioglu, M.; Bain, J.; Muehlbauer, M.; Stevens, R.; Ilkayeva, O.; Dolinsky, D.; Armstrong, S.; Irizarry, K.; et al. Sex Differences in Biomarkers Associated With Insulin Resistance in Obese Adolescents: Metabolomic Profiling and Principal Components Analysis. J. Clin. Endocrinol. Metab. 2014, 99, 4730–4739. [Google Scholar] [CrossRef]
  31. Lew, J.; Sanghavi, M.; Ayers, C.R.; McGuire, D.K.; Omland, T.; Atzler, D.; Gore, M.O.; Neeland, I.; Berry, J.D.; Khera, A.; et al. Sex-Based Differences in Cardiometabolic Biomarkers Clinical Perspective. Circulation 2017, 135, 544–555. [Google Scholar] [CrossRef] [PubMed]
  32. Morgan, C.P.; Bale, T.L. Sex differences in microRNA regulation of gene expression: no smoke, just miRs. Biol. Sex Differ. 2012, 3, 22. [Google Scholar] [CrossRef]
  33. Behar, D.M.; Yunusbayev, B.; Metspalu, M.; Metspalu, E.; Rosset, S.; Parik, J.; Rootsi, S.; Chaubey, G.; Kutuev, I.; Yudkovsky, G.; et al. The genome-wide structure of the Jewish people. Nature 2010, 466, 238–242. [Google Scholar] [CrossRef]
  34. Valadi, H.; Ekström, K.; Bossios, A.; Sjöstrand, M.; Lee, J.J.; Lötvall, J.O. Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat. Cell Biol. 2007, 9, 654–659. [Google Scholar] [CrossRef]
  35. Huang-Doran, I.; Zhang, C.-Y.; Vidal-Puig, A. Extracellular Vesicles: Novel Mediators of Cell Communication In Metabolic Disease. Trends Endocrinol. Metab. 2017, 1, 3–18. [Google Scholar] [CrossRef]
  36. Wang, B.; Wang, H.; Yang, Z. MiR-122 inhibits cell proliferation and tumorigenesis of breast cancer by targeting IGF1R. PLoS ONE 2012, 7, e47053. [Google Scholar] [CrossRef] [PubMed]
  37. Nassirpour, R.; Mehta, P.P.; Yin, M.-J. miR-122 regulates tumorigenesis in hepatocellular carcinoma by targeting AKT3. PLoS ONE 2013, 8, e79655. [Google Scholar] [CrossRef] [PubMed]
  38. Basu, S.; Bhattacharyya, S.N. Insulin-like growth factor-1 prevents miR-122 production in neighbouring cells to curtail its intercellular transfer to ensure proliferation of human hepatoma cells. Nucleic Acids Res. 2014, 42, 7170–7185. [Google Scholar] [CrossRef] [PubMed]
  39. Gao, W.; He, H.-W.; Wang, Z.-M.; Zhao, H.; Lian, X.-Q.; Wang, Y.-S.; Zhu, J.; Yan, J.-J.; Zhang, D.-G.; Yang, Z.-J.; et al. Plasma levels of lipometabolism-related miR-122 and miR-370 are increased in patients with hyperlipidemia and associated with coronary artery disease. Lipids Health Dis. 2012, 11, 55. [Google Scholar] [CrossRef]
  40. Thomou, T.; Mori, M.A.; Dreyfuss, J.M.; Konishi, M.; Sakaguchi, M.; Wolfrum, C.; Rao, T.N.; Winnay, J.N.; Garcia-Martin, R.; Grinspoon, S.K.; et al. Adipose-derived circulating miRNAs regulate gene expression in other tissues. Nature 2017, 542, 450–455. [Google Scholar] [CrossRef]
  41. Lee, M.-L.T.; Whitmore, G.A. Power and sample size for DNA microarray studies. Stat. Med. 2002, 21, 3543–3570. [Google Scholar] [CrossRef] [PubMed]
  42. Meerson, A.; Ploug, T. Assessment of six commercial plasma small RNA isolation kits using qRT-PCR and electrophoretic separation: Higher recovery of microRNA following ultracentrifugation. Biol. Meth. Prot. 2016, 1, bpw003. [Google Scholar] [CrossRef]
  43. Pezzolesi, M.G.; Satake, E.; McDonnell, K.P.; Major, M.; Smiles, A.M.; Krolewski, A.S. Circulating TGF-β1–Regulated miRNAs and the Risk of Rapid Progression to ESRD in Type 1 Diabetes. Diabetes 2015, 64, 3285–3293. [Google Scholar] [CrossRef] [PubMed]
  44. Jones, A.; Danielson, K.M.; Benton, M.C.; Ziegler, O.; Shah, R.; Stubbs, R.S.; Das, S.; Macartney-Coxson, D. miRNA signatures of insulin resistance in obesity. Obesity 2017, 25, 1734–1744. [Google Scholar] [CrossRef]
  45. Meerson, A.; Eliraz, Y.; Yehuda, H.; Knight, B.; Crundwell, M.; Ferguson, D.; Lee, B.P.; Harries, L.W. Obesity impacts the regulation of miR-10b and its targets in primary breast tumors. BMC Cancer 2019, 19, 86. [Google Scholar] [CrossRef] [PubMed]
Ncrna 05 00032 g001 550
Figure 1. (A) Relative mean levels of plasma microRNAs in the three subject groups, as measured by quantitative reverse transcription and polymerase chain reaction (qRT-PCR). The data are normalized (the levels of each miRNA can be compared between groups, but the levels of different miRNAs cannot be compared). Bars, standard error. N(A) = 30, N(B) = 29, N(C) = 29. *: p < 0.05; **: p < 0.001 (t-test). (B) Relative mean levels of plasma miR-16-2-3p, miR-146a-5p, and miR-423 in the three subject groups stratified by sex, as measured by qRT-PCR. The data are normalized (the levels of each miRNA can be compared between groups, but the levels of different miRNAs cannot be compared). Bars, standard error. Numbers of samples in each category appear in Table 3. *: p < 0.05; **: p < 0.01 (t-test). (C,D) Relative miR-486-3p levels (determined by qRT-PCR) plotted against low-density lipoprotein (LDL) levels in female subjects (B, n = 36) and against high-density lipoprotein (HDL) levels in male subjects (C, n = 52). Note logarithmic scale of horizontal axis in B and vertical axis in both B and C, used to improve resolution. Trendlines are logarithmic.
Figure 1. (A) Relative mean levels of plasma microRNAs in the three subject groups, as measured by quantitative reverse transcription and polymerase chain reaction (qRT-PCR). The data are normalized (the levels of each miRNA can be compared between groups, but the levels of different miRNAs cannot be compared). Bars, standard error. N(A) = 30, N(B) = 29, N(C) = 29. *: p < 0.05; **: p < 0.001 (t-test). (B) Relative mean levels of plasma miR-16-2-3p, miR-146a-5p, and miR-423 in the three subject groups stratified by sex, as measured by qRT-PCR. The data are normalized (the levels of each miRNA can be compared between groups, but the levels of different miRNAs cannot be compared). Bars, standard error. Numbers of samples in each category appear in Table 3. *: p < 0.05; **: p < 0.01 (t-test). (C,D) Relative miR-486-3p levels (determined by qRT-PCR) plotted against low-density lipoprotein (LDL) levels in female subjects (B, n = 36) and against high-density lipoprotein (HDL) levels in male subjects (C, n = 52). Note logarithmic scale of horizontal axis in B and vertical axis in both B and C, used to improve resolution. Trendlines are logarithmic.
Ncrna 05 00032 g001
Ncrna 05 00032 g002 550
Figure 2. (A) Relative mean levels of plasma miR-183-5p and miR-16-2-3p in the three subject groups (A, B, C) with ethnic affiliation of Muslim Arab (M) or Jew (J), as measured by qRT-PCR. The data are normalized (the levels of each miRNA can be compared between groups, but the levels of different miRNAs cannot be compared). Bars, standard error. Numbers of samples in each category appear in Supplementary Table S1. *: p < 0.05 (t-test). (B) Mean blood pressure levels (in mmHg) of the three subject groups (A, B, C) with ethnic affiliation of Muslim Arab (M) or Jew (J). SBP, systolic; DBP, diastolic. Bars, standard error. Numbers of samples in each category appear in Supplementary Table S1. *: p < 0.05 (t-test).
Figure 2. (A) Relative mean levels of plasma miR-183-5p and miR-16-2-3p in the three subject groups (A, B, C) with ethnic affiliation of Muslim Arab (M) or Jew (J), as measured by qRT-PCR. The data are normalized (the levels of each miRNA can be compared between groups, but the levels of different miRNAs cannot be compared). Bars, standard error. Numbers of samples in each category appear in Supplementary Table S1. *: p < 0.05 (t-test). (B) Mean blood pressure levels (in mmHg) of the three subject groups (A, B, C) with ethnic affiliation of Muslim Arab (M) or Jew (J). SBP, systolic; DBP, diastolic. Bars, standard error. Numbers of samples in each category appear in Supplementary Table S1. *: p < 0.05 (t-test).
Ncrna 05 00032 g002
Table
Table 1. Discriminant analysis of plasma levels of miR-146a-5p, miR-16-2-3p, miR-126-5p, miR-30d, and miR-423 in distinguishing early vs. complicated diabetes mellitus (DM).
Table 1. Discriminant analysis of plasma levels of miR-146a-5p, miR-16-2-3p, miR-126-5p, miR-30d, and miR-423 in distinguishing early vs. complicated diabetes mellitus (DM).
ActualCalculatedTotal
Early DMComplicated DM
All T2DM samplesEarly DM22729
Complicated DM62127
76.7% of the cases were classified correctly
DM men onlyEarly DM17118
Complicated DM51318
83.3% of the cases were classified correctly
DM women onlyEarly DM7411
Complicated DM279
70% of the cases were classified correctly
In the entire cohort (men + women), significant (p < 0.05) differences in the plasma levels of miR-30d, miR-146a-5p, miR-28-3p, miR-486-3p, and miR-423 were observed between the groups (Table 2). In addition, miR-183-5p was significantly up-regulated in early type 2 DM (T2DM) (group B) compared to healthy controls (group A), only in female subjects (as opposed to the male subjects and the entire cohort).
Table
Table 2. Summary of significant (p < 0.05, t-test) differences between plasma miRNA levels in groups of subjects as indicated. Group A: Healthy volunteers; Group B: Early-stage T2DM with no known renal or vascular pathologies; Group C: Late-stage T2DM with renal and/or vascular complications.
Table 2. Summary of significant (p < 0.05, t-test) differences between plasma miRNA levels in groups of subjects as indicated. Group A: Healthy volunteers; Group B: Early-stage T2DM with no known renal or vascular pathologies; Group C: Late-stage T2DM with renal and/or vascular complications.
miRNAGroupsFold Change in Levelsp-Value
Entire cohort (n = 88)miR-30dA vs. C0.640.003
(group A = 30, group B = 29, group C = 29)miR-146a-5pA vs. C1.300.027
miR-28-3pB vs. C1.430.029
miR-486-3pA vs. B2.670.013
B vs. C0.420.038
miR-423A vs. B0.520.00001
B vs. C2.430.0003
Women only (n = 36)miR-30dA vs. C0.690.043
(group A = 15, group B = 11, group C = 10)miR-183-5pA vs. B4.170.031
miR-423A vs. B0.510.0027
Men only (n = 52)miR-30dA vs. C0.590.017
(group A = 15, group B = 18, group C = 19)miR-146a-5pA vs. B1.460.033
A vs. C1.500.022
miR-486-3pA vs. B2.190.0009
B vs. C0.530.0013
Within healthy control group A, significant (p < 0.05) differences in the plasma levels of miR-16-2-3p, miR-146a-5p, and miR-423 were observed between men and women (Figure 1B). Additionally, a significant (p = 0.007) difference in the plasma levels of miR-16-2-3p was observed between women and men in the complicated T2DM group C, while miR-423 showed a similar trend, which did not reach statistical significance (Figure 1B).
Table
Table 3. Summary of significant (p < 0.05) Pearson correlations between plasma miRNA levels and clinical measurements as indicated. F—female, M—male. NA refers to the number of subjects in group A, etc.
Table 3. Summary of significant (p < 0.05) Pearson correlations between plasma miRNA levels and clinical measurements as indicated. F—female, M—male. NA refers to the number of subjects in group A, etc.
miRNAMeasurementR Valuep-Value
entire cohortmiR-183-5pBMI0.330.048
(N = 88; NA = 30, NB = 29, NC = 29)miR-486-3pLDL0.470.009
F onlymiR-4301LDL0.520.002
(N = 36; NA = 15, NB = 11, NC = 10)miR-183-5pWEIGHT0.380.040
BMI0.500.005
ABD. GIRTH0.380.037
miR-486-3pLDL0.710.000004
miR-122-5pDBP0.450.006
HBA1C0.430.010
miR-423AGE−0.350.031
WEIGHT−0.530.001
BMI−0.550.0006
ABD. GIRTH−0.430.007
GLU. LEVEL−0.390.016
HBA1C−0.450.006
M onlymiR-16-2-3pHEIGHT0.390.009
(N = 52; NA = 15, NB = 18, NC = 19) SBP−0.350.015
HDL−0.340.019
miR-30dAGE−0.310.032
SBP−0.340.017
miR-4301GLU. LEVEL0.310.035
miR-27b-3pWEIGHT0.450.003
BMI0.390.009
miR-146a-5pAGE0.450.001
BMI0.370.013
ABD. GIRTH0.310.026
SBP0.340.016
miR-486-3pHEIGHT0.430.004
HDL−0.480.0005
miR-122-5pABD. GIRTH−0.280.048

Share and Cite

MDPI and ACS Style

Meerson, A.; Najjar, A.; Saad, E.; Sbeit, W.; Barhoum, M.; Assy, N. Sex Differences in Plasma MicroRNA Biomarkers of Early and Complicated Diabetes Mellitus in Israeli Arab and Jewish Patients. Non-Coding RNA 2019, 5, 32. https://doi.org/10.3390/ncrna5020032

AMA Style

Meerson A, Najjar A, Saad E, Sbeit W, Barhoum M, Assy N. Sex Differences in Plasma MicroRNA Biomarkers of Early and Complicated Diabetes Mellitus in Israeli Arab and Jewish Patients. Non-Coding RNA. 2019; 5(2):32. https://doi.org/10.3390/ncrna5020032

Chicago/Turabian Style

Meerson, Ari, Azwar Najjar, Elias Saad, Wisam Sbeit, Masad Barhoum, and Nimer Assy. 2019. "Sex Differences in Plasma MicroRNA Biomarkers of Early and Complicated Diabetes Mellitus in Israeli Arab and Jewish Patients" Non-Coding RNA 5, no. 2: 32. https://doi.org/10.3390/ncrna5020032

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop